AT concentrate and recombinant thrombomodulin are commonly used for DIC, while eculizumab is effective for complement‐mediated TMA, such as aHUS, and rituximab is beneficial for TTP in patients with high ADAMTS13 inhibitor titers. This evidence concerns the gene ADAMTS13 and thrombotic thrombocytopenic purpura.